# Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy

> **NCT01508468** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 80 (actual)

## Conditions studied

- Idiopathic Membranous Nephropathy

## Interventions

- **DRUG:** symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
- **DRUG:** experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)

## Key facts

- **NCT ID:** NCT01508468
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2016-08-31
- **Final completion:** 2016-08-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508468, "Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01508468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*